BDX vs RMD
Becton Dickinson and ResMed, both Healthcare
Becton Dickinson is the larger company at $40B against $27B. On trailing earnings RMD is the cheaper of the two at a P/E of 22.1 against 55.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year BDX returned +26% against -15% for RMD. The RyuScore puts RMD ahead, 83 against 62 out of 100.
| Figure | BDX | RMD |
|---|---|---|
| Last close | $184 | $230 |
| Market cap | $40B | $27B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 55.3 | 22.1 |
| Dividend yield | 2.3% | 1.0% |
| 1-year return | +26% | -15% |
| 5-year return | +0.7% | -17% |
| RyuScoresector-relative, 1–10 | 62/100 | 83/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Becton Dickinson
Revenue of $5.0B in Q3 2026, net income $377M. Its largest reported line is Connected Care, 38% of the disclosed total.
ResMed
Revenue of $1.5B in Q4 2026, net income $383M. Its largest reported line is Sleep And Breathing Health, 88% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.